Postautologous stem cell transplantation engraftment syndrome: Improved treatment and outcomes.
Ziyang LiuShuyao ZhangBiljana HornJan S MorebPublished in: Clinical transplantation (2020)
Postautologous stem cell transplantation (ASCT) engraftment syndrome (ES) is a well-known clinical complication; however, many aspects remain largely controversial. In this retrospective study, we reviewed records of 156 ASCTs done over 2 years in our institution. Our results show that 45 (34 multiple myeloma/amyloidosis and 11 lymphoma) of 156 adult patients (29%) were diagnosed with ES. Patients with ES were significantly more likely to have fever, rash, and diarrhea upon engraftment. Risk factors for ES included shorter time from diagnosis to ASCT (P = .029), and lower number of pretransplant treatment regimens (0.012). Post-ASCT, patients with ES had significantly lower absolute lymphocyte count on first engraftment day (P = .014). Most ES patients received treatment with steroids. Initial dose of prednisone/methylprednisolone was 2 mg/kg (n = 34), 1 mg/kg (n = 7), while four patients received 1000 mg IV with median length of therapy 7.5 days. One ES patient with inadequate steroid therapy died of ES complications, while another developed respiratory failure requiring intubation but had full recovery with steroids treatment. In conclusion, patients with shorter time from diagnosis to ASCT and with less prior therapy are more likely to develop ES. Overall survival of ES patients has improved with greater awareness of the diagnosis and earlier use of steroids.
Keyphrases
- stem cell transplantation
- end stage renal disease
- high dose
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- multiple myeloma
- case report
- intensive care unit
- cardiac arrest
- extracorporeal membrane oxygenation
- risk factors
- mesenchymal stem cells
- skeletal muscle
- patient reported outcomes
- adipose tissue
- replacement therapy
- patient reported
- insulin resistance